MIRA's Ketamir-2 manuscript accepted for publication; shows superior efficacy in neuropathic pain models

MIRA PHARMACEUTICALS, INC.

Ketamir-2 manuscript accepted in Frontiers in Pharmacology; outperformed ketamine, pregabalin, gabapentin in preclinical models.
Restored sensory function and reversed pain behaviors across genders and species in two validated models.
Global neuropathic pain market: $7.97B (2024) projected to $16.79B by 2034, CAGR 7.73%; North America ~$3.7-3.9B.
Company plans to submit Phase 2a protocol to FDA in Q4 2025, aiming to initiate study by year-end.
Also evaluating Ketamir-2 for depression, anxiety, PTSD, and as a topical formulation for localized pain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.